高风险APOL1基因型患者中孟德尔肾脏病的患病率
该研究分析了2020至2021年美国商业基因检测的15181例患者,发现6.8%具有高风险APOL1基因型,其中约10%同时存在孟德尔肾脏病。在近期非洲基因组 ancestry 患者中,高风险APOL1基因型者的孟德尔肾脏病患病率低于低风险基因型者。
要点
- 高风险APOL1基因型者中孟德尔肾脏病患病率约10%。
- 近期非洲 ancestry 患者中,高风险APOL1基因型者孟德尔病患病率低于G0/G0者。
- PKD1和COL4A4致病变异频率在高风险与低风险APOL1基因型间存在差异。
核心结论
- 在商业基因检测人群中,高风险APOL1基因型患者中约10%存在孟德尔肾脏病。
- 高风险APOL1基因型者孟德尔肾脏病患病率低于单风险等位基因携带者和G0/G0基因型者。
研究设计与样本
- 回顾性分析2020至2021年美国商业外显子组测序数据,共15181例接受孟德尔肾脏病基因检测的患者。
- 根据APOL1基因型分为高风险(G1/G1、G1/G2、G2/G2)、单风险(G1/G0、G2/G0)和G0/G0三组。
主要发现
- 15181例中3119例(20.5%)有孟德尔肾脏病分子诊断,1035例(6.8%)为高风险APOL1基因型。
- 近期非洲基因组 ancestry 患者中,高风险APOL1基因型者孟德尔肾脏病患病率为9.6%(91/944)。
- 近期非洲基因组 ancestry 患者中,单风险APOL1等位基因携带者孟德尔肾脏病患病率为13.6%(198/1453)。
- 近期非洲基因组 ancestry 患者中,G0/G0基因型者孟德尔肾脏病患病率为16.6%(213/1281)。
- 合并孟德尔肾脏病的近期非洲 ancestry 患者中,PKD1致病变异在高风险组占19.8%、低风险组占30.2%;COL4A4致病变异在高风险组占24.2%、低风险组占10.5%。
临床怎么用
- 对高风险APOL1基因型患者应警惕合并孟德尔肾脏病的可能,并考虑进一步基因评估。
- 在高风险APOL1基因型患者中,PKD1和COL4A4等基因的致病变异分布与低风险者不同,可能影响诊断思路。
局限性
- 研究基于接受商业基因检测的选择性人群,结果可能无法推广至一般人群。
- 未报告其他遗传或非遗传修饰因素对结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Among individuals with high-risk APOL1 genotypes, the lifetime risk of developing kidney failure is ∼15%, indicating that other genetic variants or nongenetic modifiers likely contribute substantially to an individual patient's risk of progressive kidney disease. Here, we estimate the prevalence and distribution of Mendelian kidney diseases among patients with high-risk APOL1 genotypes undergoing commercial genetic testing in the United States. METHODS: We analyzed clinical exome sequencing data from 15,181 individuals undergoing commercial genetic testing for Mendelian kidney disease in the United States from 2020 to 2021. We identified patients with high-risk APOL1 genotypes by the presence of G1/G1, G1/G2, or G2/G2 alleles. Patients carrying single risk APOL1 alleles were identified as G1/G0, G2/G0; the remainder of patients were G0/G0. We estimated the prevalence and distribution of Mendelian kidney disease stratified by APOL1 genotype and genetically predicted ancestry. RESULTS: Of 15,181 patients, 3119 had genetic testing results consistent with a molecular diagnosis of Mendelian kidney disease (20.5%). Of 15,181 patients, 1035 (6.8%) had high-risk APOL1 genotypes. Among patients with recent genomic African ancestry, the prevalence of Mendelian kidney diseases was lower in those with high-risk APOL1 genotypes (9.6%; n = 91/944) compared with single risk APOL1 allele carriers (13.6%; n = 198/1453) and those with G0/G0 APOL1 genotypes (16.6%; n = 213/1281). Among patients with Mendelian kidney disease and recent genomic African ancestry, we observed differences in the prevalence of pathogenic/likely pathogenic variants in PKD1 (19.8% in high-risk vs. 30.2% in low-risk genotypes), and COL4A4 (24.2% in high-risk vs. 10.5% in low-risk genotypes). CONCLUSION: In this selected population of patients undergoing clinical genetic testing, we found evidence of Mendelian kidney disease in ∼10% patients with high-risk APOL1 genotypes.
引用
- da Silva Francisco R, Punj S, Vincent L, et al. Prevalence of Mendelian Kidney Disease Among Patients With High-Risk APOL1 Genotypes Undergoing Commercial Genetic Testing in the United States. Kidney Int Rep. 2024. PMID: 39291188. doi:10.1016/j.ekir.2024.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。